DOE OSTI · 1673355
Favipiravir Flow Synthesis
Abstract
Researchers at Los Alamos have invented a novel flow/batch chemistry synthetic process to produce the small molecule anti-viral favipiravir more cheaply and rapidly to enable on-demand production for pandemic response. Current methods for synthesizing favipiravir are constrained by long reaction times and low yields. If ongoing clinical trials for favipiravir demonstrate its effectiveness as a COVID-19 antiviral, and as a broad spectrum anti-viral for treating future viral outbreaks, this synthesis would help alleviate potential drug shortages and supply chain issues for the manufacturing and availability of this small molecule anti-viral. This U.S.-based synthesis route would be capable of scale-up for making large (kilogram) amounts of favipiravir as needed to assist with clinical trial needs and demand for patient treatment, and can also produce isotopically labeled favipiravir. We are seeking a CRADA partner to finalize method development who has interest in licensing the method and employing it for domestic production.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Evans, Amanda Christine. 2020-10-08. Favipiravir Flow Synthesis. https://doi.org/10.2172/1673355
Cite the original work for its findings. Save a collection to share your selection of sources.